Blue Savant AI

About Blue Savant AI

BlueSavant AI utilizes a proprietary machine learning model to analyze genetic expressions from standard blood samples, achieving over 90% precision in identifying Autism Spectrum Disorder (ASD) in children as young as 18 months. This early detection addresses the significant delay in ASD diagnosis, which often occurs after the critical intervention window has passed.

```xml <problem> Current methods for diagnosing Autism Spectrum Disorder (ASD) rely on behavioral assessments that are often subjective and can only be administered after a child has reached a certain developmental stage. This leads to significant delays in diagnosis, with most children in the US not being diagnosed until after the age of 4, missing critical early intervention opportunities. The lack of objective, early diagnostic tools contributes to the rising societal costs associated with ASD. </problem> <solution> BlueSavant AI offers an early detection solution for ASD through a standard blood test analyzed with a proprietary machine learning model. By analyzing genetic expressions, the test can identify ASD in children as young as 18 months with over 90% precision. This early identification enables timely behavioral interventions, leading to improved outcomes for children with ASD, including enhancements in IQ, verbal communication, and social abilities. The technology provides an objective measure that overcomes the limitations of traditional behavioral assessments, allowing for earlier diagnosis and intervention. </solution> <features> - Analyzes genetic expressions from standard blood samples using a proprietary machine learning model. - Achieves over 90% precision in identifying Autism Spectrum Disorder (ASD) in children as young as 18 months. - Provides an objective measure for ASD diagnosis, reducing reliance on subjective behavioral assessments. </features> <target_audience> The primary target audience includes pediatricians, neurologists, and other healthcare providers involved in early childhood development, as well as parents seeking early and accurate ASD diagnosis for their children. </target_audience> ```

What does Blue Savant AI do?

BlueSavant AI utilizes a proprietary machine learning model to analyze genetic expressions from standard blood samples, achieving over 90% precision in identifying Autism Spectrum Disorder (ASD) in children as young as 18 months. This early detection addresses the significant delay in ASD diagnosis, which often occurs after the critical intervention window has passed.

Where is Blue Savant AI located?

Blue Savant AI is based in Wilmington, United States.

When was Blue Savant AI founded?

Blue Savant AI was founded in 2024.

Who founded Blue Savant AI?

Blue Savant AI was founded by Jacob Thaysen.

  • Jacob Thaysen - CEO
Location
Wilmington, United States
Founded
2024
Employees
5 employees
Looking for specific startups?
Try our free semantic startup search

Blue Savant AI

Score: 77/100
AI-Generated Company Overview (experimental) – could contain errors

Executive Summary

BlueSavant AI utilizes a proprietary machine learning model to analyze genetic expressions from standard blood samples, achieving over 90% precision in identifying Autism Spectrum Disorder (ASD) in children as young as 18 months. This early detection addresses the significant delay in ASD diagnosis, which often occurs after the critical intervention window has passed.

bluesavant.net10+
cb
Crunchbase
Founded 2024 – Wilmington, United States

Funding

No funding information available. Click "Fetch funding" to run a targeted funding scan.

Team (5+)

Jacob Thaysen

CEO

Company Description

Problem

Current methods for diagnosing Autism Spectrum Disorder (ASD) rely on behavioral assessments that are often subjective and can only be administered after a child has reached a certain developmental stage. This leads to significant delays in diagnosis, with most children in the US not being diagnosed until after the age of 4, missing critical early intervention opportunities. The lack of objective, early diagnostic tools contributes to the rising societal costs associated with ASD.

Solution

BlueSavant AI offers an early detection solution for ASD through a standard blood test analyzed with a proprietary machine learning model. By analyzing genetic expressions, the test can identify ASD in children as young as 18 months with over 90% precision. This early identification enables timely behavioral interventions, leading to improved outcomes for children with ASD, including enhancements in IQ, verbal communication, and social abilities. The technology provides an objective measure that overcomes the limitations of traditional behavioral assessments, allowing for earlier diagnosis and intervention.

Features

Analyzes genetic expressions from standard blood samples using a proprietary machine learning model.

Achieves over 90% precision in identifying Autism Spectrum Disorder (ASD) in children as young as 18 months.

Provides an objective measure for ASD diagnosis, reducing reliance on subjective behavioral assessments.

Target Audience

The primary target audience includes pediatricians, neurologists, and other healthcare providers involved in early childhood development, as well as parents seeking early and accurate ASD diagnosis for their children.